Cyclo-oxygenase inhibitors in ophthalmology.
Cyclo-oxygenase inhibitors, which are formulated as ophthalmic eyedrop preparations, have recently become commercially available for use by ophthalmologists in the United States to inhibit intraoperative miosis during cataract surgery and to prevent postoperative inflammation. In addition, they are available worldwide as ocular antiinflammatory drugs and are used in the prevention and treatment of pseudophakic and aphakic cystoid macular edema. Understanding the rationale behind the use of these agents requires an understanding of the pathophysiology of the cyclo-oxygenase inhibitors. In this review recent advances in laboratory and clinical science are emphasized. The role of COIs during and following surgery is examined.
Flach
A J
AJ
Department of Ophthalmology, University of California, San Francisco.
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D001036:Aphakia, Postcataract / Q000188:drug therapy / Q000517:prevention & control; D002387:Cataract Extraction; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D009877:Endophthalmitis / Q000517:prevention & control; D006801:Humans; D007431:Intraoperative Complications / Q000517:prevention & control; D007910:Lenses, Intraocular; D008269:Macular Edema / Q000188:drug therapy / Q000517:prevention & control; D015877:Miosis / Q000517:prevention & control; D009883:Ophthalmic Solutions / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D009883:Ophthalmic Solutions